Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Spruce Biosciences announced the successful closure of its initial public offering, selling 6,900,000 shares at $15.00 each, raising gross proceeds of $103.5 million. The offering included 900,000 shares from underwriters' exercised options. Trading commenced on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol SPRB. Spruce focuses on developing therapies for rare endocrine disorders, specifically targeting congenital adrenal hyperplasia with its product candidate, tildacerfont.